Trevi Therapeutics Stock Price, News & Analysis

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, has announced its participation in six major healthcare and industry conferences throughout September 2025. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough conditions, will be represented by senior management at various events including the Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, Leerink Partners Biopharma Summit, and the European Respiratory Society Congress.

A notable highlight includes a fireside chat scheduled for September 9 at 4:05 p.m. ET during the Morgan Stanley conference, which will be available via live presentation.

Trevi Therapeutics (NASDAQ: TRVI) reported significant achievements in Q2 2025, highlighted by positive Phase 2b CORAL trial results for Haduvio™ in treating chronic cough in IPF patients. The trial demonstrated statistically significant reductions in 24-hour cough frequency across all dose groups, with the highest dose (108mg BID) achieving a 60.2% reduction from baseline (p<0.0001).

The company successfully completed a $115 million underwritten offering in June 2025, ending Q2 with $203.9 million in cash and equivalents, extending runway into 2029. Q2 financial results showed R&D expenses of $9.4 million (down from $10.0 million in Q2 2024) and a net loss of $12.3 million. The company plans to request an End-of-Phase 2 FDA meeting in Q4 2025 and aims to initiate Phase 3 trials in H1 2026.

Trevi Therapeutics (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, will host a conference call and webcast on August 7, 2025, at 4:30 p.m. ET to discuss Q2 2025 financial results and provide a corporate update. The company is developing Haduvio™ (oral nalbuphine ER) for treating chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough.

Investors can join via phone at (877) 870 4263 (domestic) or (412) 317 0790 (international). A webcast will be available in the 'Investors & News' section of TreviTherapeutics.com, with a 30-day replay option.

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming biotech conferences in August 2025. The company, which is developing Haduvio™ (oral nalbuphine ER) for chronic cough conditions, will be represented at Oppenheimer's 2025 Biotech in the Berkshires (August 4-6) and Stifel's 2025 Biotech Summer Summit (August 11-13).

President and CEO Jennifer Good will attend both events, with Chief Commercial Officer Farrell Simon joining for a fireside chat at the Stifel conference on August 11 at 1:00 p.m. ET.

Trevi Therapeutics (NASDAQ:TRVI), a clinical-stage biopharmaceutical company, announced its participation in the upcoming Leerink Partners Therapeutics Forum focused on I&I and Metabolism. The event will be held from July 8-9 in Boston, Massachusetts. The company's senior management, including President and CEO Jennifer Good and CFO Lisa Delfini, will be in attendance.

Trevi is currently developing Haduvio™ (oral nalbuphine ER), an investigational therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Trevi Therapeutics (NASDAQ: TRVI) has successfully closed its previously announced underwritten public offering, raising approximately $115.1 million before expenses. The offering included 20,010,000 shares of common stock priced at $5.75 per share, with underwriters fully exercising their option to purchase an additional 2,610,000 shares. The biopharmaceutical company, which is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF and RCC patients, conducted the offering through joint book-running managers Morgan Stanley, Leerink Partners, Stifel, and Cantor. The offering was made pursuant to a shelf registration statement on Form S-3 filed with the SEC.

Trevi Therapeutics (NASDAQ: TRVI) has announced the pricing of an underwritten public offering of 17.4 million shares of common stock at $5.75 per share, aiming to raise $100 million before deducting underwriting costs. The company, which is developing Haduvio for chronic cough in IPF and RCC patients, has also granted underwriters a 30-day option to purchase up to 2.61 million additional shares. The offering is expected to close around June 5, 2025, with Morgan Stanley, Leerink Partners, Stifel, and Cantor serving as joint book-running managers. The shares are being offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on August 15, 2023.

Trevi Therapeutics (NASDAQ: TRVI) has announced a proposed public offering of $100 million worth of common stock shares, with an additional 30-day option for underwriters to purchase up to $15 million more shares. The clinical-stage biopharmaceutical company, which is developing Haduvio (oral nalbuphine ER) for chronic cough treatment in IPF and RCC patients, will offer all shares through joint book-running managers Morgan Stanley, Leerink Partners, Stifel, and Cantor. The offering will be conducted under a previously filed shelf registration statement that was declared effective by the SEC on August 15, 2023. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

Trevi Therapeutics (NASDAQ: TRVI) announced positive Phase 2b CORAL trial results for Haduvio in treating chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The trial met its primary endpoint with significant reductions in 24-hour cough frequency across all dose groups, with the highest dose (108mg BID) achieving a -43.3% placebo-adjusted reduction. The drug demonstrated rapid efficacy at Week 2 and was well-tolerated, with similar discontinuation rates between treatment (5.6%) and placebo (5.0%) groups. Secondary endpoints showed significant improvements in cough severity and patient-reported outcomes. The company plans to meet with the FDA and initiate Phase 3 trials in first half of 2026.